Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 24;14(3):244.
doi: 10.3390/jpm14030244.

Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety

Andrej Belančić  1   2 , Tea Strbad  3 , Marta Kučan Štiglić  4 , Dinko Vitezić  1   2
Affiliations

Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety

Andrej Belančić et al. J Pers Med. .

Abstract

(1) Background: Data on combination or sequential treatment of spinal muscular atrophy (SMA) with disease-modifying drugs (DMDs) are missing and the latter field is poorly understood. The currently available data of patients on risdiplam previously treated with nusinersen are coming from exploratory research mainly focused on safety. Our aim was to investigate the real-world effectiveness (hypothesising non-inferiority) and safety profile of risdiplam in a paediatric-and-adult nusinersen-risdiplam spinal muscular atrophy switch cohort. (2) Methods: A retrospective and anonymous collection of relevant demographic and clinical data for all Croatian SMA patients switched from nusinersen to risdiplam up to September 2023 (reimbursed by Croatian Health Insurance Fund-CHIF) was performed using the CHIF database and associated reimbursement documentation. Patients were included in effectiveness and safety analysis if they met the following inclusion criteria: (i) risdiplam was reimbursed by the CHIF; (ii) the patient received at least six doses of nusinersen before the switch to risdiplam; (iii) there was no relevant pause between the latter disease-modifying drugs; (iv) availability of all prespecified studied data and parameters. (3) Results: In total, 17 patients met the inclusion criteria (58.9% female; median age 12.75 (3.0-44.5) years). In our 'switch' cohort, we demonstrated a non-inferiority of risdiplam to nusinersen in the SMA 1 (+1.0 in CHOP INTEND; p = 0.067), SMA 3p (+0.7 in HFMSE; p = 0.897), and SMA 3a (+0.8 in RHS; p = 0.463) subpopulations, during a one-year follow-up period. There were no reports on respiratory function worsening, feeding worsening, and no lethal events. No new safety concerns were identified, except for the weight gain that arose as a new potential adverse drug reaction 'signal' in two patients. (4) Conclusions: We have reported pivotal real-world findings on switching SMA patients from nusinersen to risdiplam and demonstrated its effectiveness (non-inferiority), safety, and tolerability in a heterogenous paediatric-and-adult 'switch' cohort; this will further increase the quality and standards of care as well as safety of a notable portion of SMA patients, especially for those who demand the switch from nusinersen to other DMDs for clinical or personal reasons.

Keywords: effectiveness; nusinersen; real-world data; risdiplam; spinal muscular atrophy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
(A): CHOP INTEND (n = 6) before nusinersen introduction (8.5 ± 7.7) vs. at the time of the switch (33.7 ± 23.7; p = 0.031); (B): HFMSE (n = 4) before nusinersen introduction (46.5 ± 11.9) vs. at the time of the switch (54.8 ± 10.2; p = 0.125); (C): RHS (n = 7) before nusinersen introduction (38.6 ± 14.3) vs. at the time of the switch (39.1 ± 12.7; p = 0.916).
Figure 2
Figure 2
(A): CHOP INTEND scores at the time of the switch (baseline) and during the follow-up; (B): HFMSE scores at the time of the switch (baseline) and during the follow-up; (C): RHS scores at the time of the switch (baseline) and during the follow-up. Measures of central tendency and measures of spread as well as p values are presented within Table 2.
Figure 2
Figure 2
(A): CHOP INTEND scores at the time of the switch (baseline) and during the follow-up; (B): HFMSE scores at the time of the switch (baseline) and during the follow-up; (C): RHS scores at the time of the switch (baseline) and during the follow-up. Measures of central tendency and measures of spread as well as p values are presented within Table 2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Darras B.T. Spinal muscular atrophies. Pediatr. Clin. N. Am. 2015;62:743–766. doi: 10.1016/j.pcl.2015.03.010. - DOI - PubMed
    1. Chen T.H. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand. Int. J. Mol. Sci. 2020;21:3297. doi: 10.3390/ijms21093297. - DOI - PMC - PubMed
    1. Talbot K., Tizzano E.F. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 2017;24:529–533. doi: 10.1038/gt.2017.52. - DOI - PMC - PubMed
    1. Tizzano E.F., Finkel R.S. Spinal muscular atrophy: A changing phenotype beyond the clinical trials. Neuromuscul. Disord. 2017;27:883–889. doi: 10.1016/j.nmd.2017.05.011. - DOI - PubMed
    1. Farrar M.A., Carey K.A., Paguinto S.G., Kasparian N.A., De Abreu Lourenço R. “The Whole Game is Changing and You’ve Got Hope”: Australian Perspectives on Treatment Decision Making in Spinal Muscular Atrophy. Patient. 2020;13:389–400. doi: 10.1007/s40271-020-00415-w. - DOI - PubMed

Grants and funding

This research received no external funding.